Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are already enrolled in a related study called BASECAMP-1 (run by A2 Biotherapeutics, Inc.) and whose tumour tissue testing has shown a specific genetic feature called loss of HLA-A*02, detected by a type of genetic sequencing test.
• People who have been confirmed by biopsy to have one of the following cancers that has come back, cannot be surgically removed, has spread locally, or has spread to other parts of the body: colorectal cancer, non-small cell lung cancer, head and neck squamous cell cancer, triple-negative breast cancer, kidney cell cancer, or other solid tumours that carry a protein called EGFR. At least one tumour must be measurable at 1.0 cm or larger on a CT scan.
• People who have already received the standard prior treatments required for their specific cancer type, as outlined in the trial protocol.
• People whose heart, liver, kidneys, and other organs are functioning at a level considered adequate according to the trial protocol.
• People with a performance status rating of 0 or 1 on the ECOG scale, meaning they are either fully active or have only minor restrictions in physically demanding activity (confirm with trial site).
• People with a life expectancy of at least 3 months.
• People who are willing to follow the trial's schedule of visits and assessments, including long-term safety check-ins.

Who may not be able to join:

• People whose cancer could be treated with a local treatment, or who are able to receive a standard treatment intended to cure or significantly control the disease (rather than just manage symptoms).
• People who have previously had an allogeneic stem cell transplant (a transplant using stem cells from another person).
• People who have previously had a solid organ transplant (such as a kidney, liver, or heart transplant).
• People who have received cancer treatment within 3 weeks, or within 3 half-lives of the study drug, before receiving the trial infusion (confirm with trial site for specific details).
• People who have had radiation therapy within 28 days before the trial infusion.
• People who have had unstable chest pain, an irregular heartbeat, a heart attack, or another serious heart condition within the past 6 months.
• People who have had a new blood clot in the lungs (pulmonary embolism) or a deep vein blood clot within 3 months before enrolling — though people with a history of these conditions that was more than 3 months ago and that is being adequately treated with blood thinners may still be considered.
• People who have a history of scarring or inflammation of the lungs (including caused by drugs or radiation) that required prolonged steroid treatment or other immune-suppressing treatment within the past year.
• People who need supplemental oxygen at home.
• People who are pregnant or breastfeeding.
• People of childbearing potential — male or female — who are not willing to use birth control from the time of consent through 6 months after receiving the trial infusion.

Important: Always verify eligibility with the trial site directly before applying.